Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
FMK is an inhibitor of p90 ribosomal S6 kinase 3α (RSK2; IC50 = 15 nM).1 It inhibits the C-terminal domain (CTD) kinase activity of RSK2 and inhibits EGF-induced phosphorylation of RSK2 Ser386 in serum-starved COS-7 cells (EC50 = ~200 nM). FMK (6 µM) reduces invasion, but not proliferation, of M4e, 212LN, and 37B human head and neck squamous cell carcinoma cells.2 It also inhibits FGFR3-induced growth of Ba/F3 cells in a concentration-dependent manner and induces apoptosis in OPM-1, LP-1, and KMS-18 human myeloma cells expressing the t(4;14) translocation mutation and FGFR3 when used at a concentration of 10 µM.3
WARNING This product is not for human or veterinary use.
1. Structural bioinformatics-
2. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J. Clin. Invest. 120(4), 1165-1177 (2010).
3. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12(3), 201-214 (2007).